Zusammenfassung
In den letzten Jahren wurden zahlreiche Untersuchungen zu neurobiologischen Grundlagen des Alkoholcraving durchgeführt. Von besonderem Interesse sind dabei Veränderungen des hypothalamischen Cortison-Stoffwechsels sowie des Leptin-Stoffwechsels, welcher nach neuen Untersuchungen auch mit der Pharmakotherapie in Verbindung steht. Pharmakotherapeutisch stehen mit den Substanzen Acamprosat und Naltrexon 2 Substanzen zur Rückfallprophylaxe bei Alkoholabhängigkeit zur Verfügung, wobei die Studienlage insbesondere aufgrund neuester Ergebnisse nicht unumstritten ist. Vorteilhaft scheint zumindest für einen Teil der Patienten auch eine Alkohol-aversive Behandlung mit Disulfiram zu sein. Daneben existieren eine ganze Reihe erfolgversprechender Kandidatensubstanzen. Aktuelle Forschungsbemühungen beschäftigen sich insbesondere mit einer differenziellen Indikationsstellung der Pharmakotherapie bei Alkoholabhängigkeit, unter Einbezug psychologischer und genetischer Faktoren.
Abstract
In the last years, numerous studies have been performed on neurobiological mechanisms in alcohol craving. Changes in the hypothalamic cortisol pathway and the leptin metabolism, which is also associated with pharmacological interventions, have been of special interest. With acamprosate and naltrexone two substances exist for pharmacotherapy, but recent results about the efficacy are controversial. The clinical profit of disulfiram has been shown, at least in a subgroup of patients. Besides, there are several promising candidate substances. Current investigations focus on a diffentiated pharmacotherapy of alcohol dependence, including psychological and genetic factors.
Schlüsselwörter
Craving - Alkoholabhängigkeit - HPA-Achse - Naltrexon - Acamprosat
Key words
craving - alcohol dependency - HPA-axis - naltrexone - acamprosate
Literatur
-
1
Mann K.
Neue ärztliche Aufgaben bei Alkoholproblemen.
Dtsch Arztebl..
2002;
99
32-644
-
2
Krampe H, Stawicki S, Wagner T, Bartels C, Aust C, Rüther E. et al .
Follow-up of 180 alcoholic patients for up to 7 years after outpatient treatment: impact of alcohol deterrents on outcome.
Alcohol Clin Exp Res.
2006;
30
86-95
-
3
Fritze J.
Mitteilungen der DGPPN: Ergebnisse und Kommentare zum Arzneiverordnungsreport 2005.
Der Nervenarzt..
2006;
3
376-383
-
4
Loeber S, Mann K.
Entwicklung einer evidenzbasierten Psychotherapie bei Alkoholismus: Eine Übersicht.
Nervenarzt..
2006;
77
558-566
-
5
Bowirrat A, Oscar-Berman M.
Relationship between dopaminergic neurotransmission, alcoholism, and reward deficiency syndrome.
Am J Med Genet B Neuropsychiatr Genet.
2005;
132
29-37
-
6
Heinz A, Schafer M, Higley J D, Krystal J H, Goldman D.
Neurobiological correlates of the disposition and maintenance of alcoholism.
Pharmacopsychiatry..
2003;
36 Suppl 3
S255-258
-
7
Bleich S, Degner D, Sperling W, Bönsch D, Thürauf N, Kornhuber J.
Homocysteine as a neurotoxin in chronic alcoholism.
Prog Neuropsychopharmacol Biol Psychiatry..
2004;
28
453-464
-
8
Bleich S, Degner D, Wiltfang J, Maler J M, Niedmann P, Cohrs S. et al .
Elevated homocysteine levels in alcohol withdrawal.
Alcohol Alcohol.
2000;
35
351-354
-
9
Hillemacher T, Reulbach U, Bayerlein K, Wilhelm J, Bönsch D, Sperling W. et al .
Plasma homocysteine concentrations do not influence craving in alcohol withdrawal.
Alcohol.
2004;
34
211-215
-
10
Kiefer F, Jahn H, Schick M, Wiedemann K.
Alcohol self-administration, craving and HPA-axis activity: an intriguing relationship.
Psychopharmacology (Berl).
2002;
164
239-240
-
11
Kiefer F, Wiedemann K.
Neuroendocrine pathways of addictive behaviour.
Addict Biol.
2004;
9
205-212
-
12
Olive M F, Mehmert K K, Koenig H N, Camarini R, Kim J A, Nannini M A. et al .
A role for corticotropin releasing factor (CRF) in ethanol consumption, sensitivity, and reward as revealed by CRF-deficient mice.
Psychopharmacology (Berl).
2003;
165
181-187
-
13
Fahlke C, Hard E, Thomasson R, Engel J A, Hansen S.
Metyrapone-induced suppression of corticosterone synthesis reduces ethanol consumption in high-preferring rats.
Pharmacol Biochem Behav..
1994;
48
977-981
-
14
Junghanns K, Backhaus J, Tietz U, Lange W, Bernzen J, Wetterling T. et al .
Impaired serum cortisol stress response is a predictor of early relapse.
Alcohol Alcohol.
2003;
38
189-193
-
15
Hillemacher T, Bayerlein K, Reulbach U, Sperling W, Wilhelm J, Mugele B. et al .
Influence of beer, wine and spirits consumption on craving.
Addict Biol.
2005;
10
181-186
-
16
Hillemacher T, Bayerlein K, Wilhelm J, Poleo D, Frieling H, Ziegenbein M. et al .
Volume intake and craving in alcohol withdrawal.
Alcohol Alcohol.
2006;
41
61-65
-
17
Kiefer F, Andersohn F, Jahn H, Wolf K, Raedler T J, Wiedemann K.
Involvement of plasma atrial natriuretic peptide in protracted alcohol withdrawal.
Acta Psychiatr Scand..
2002;
105
65-70
-
18
Döring W K, Herzenstiel M N, Krampe H, Jahn H, Pralle L, Sieg S. et al .
Persistent alterations of vasopressin and N-terminal proatrial natriuretic peptide plasma levels in long-term abstinent alcoholics.
Alcohol Clin Exp Res.
2003;
27
849-861
-
19
Herrmann-Lingen C, Binder L, Klinge M, Sander J, Schenker W, Beyermann B. et al .
High plasma levels of N-terminal pro-atrial natriuretic peptide associated with low anxiety in severe heart failure.
Psychosom Med.
2003;
65
517-522
-
20
Wiedemann K, Jahn H, Yassouridis A, Kellner M.
Anxiolyticlike effects of atrial natriuretic peptide on cholecystokinin tetrapeptide-induced panic attacks: preliminary findings.
Arch Gen Psychiatry.
2001;
58
371-377
-
21
Antoni F A, Hunter E F, Lowry P J, Noble J M, Seckl J R.
Atriopeptin: an endogenous corticotropin-release inhibiting hormone.
Endocrinology.
1992;
130
1753-1755
-
22
Hillemacher T, Bayerlein K, Wilhelm J, Reulbach U, Frieling H, Bönsch D. et al .
Alteration of prolactin serum levels during alcohol withdrawal correlates with craving in female patients.
Addict Biol.
2005;
10
337-343
-
23
Hillemacher T, Bayerlein K, Wilhelm J, Frieling H, Sperling W, Kornhuber J. et al .
Prolactin Serum Levels and Alcohol Craving - An Analysis Using Lesch's Typology.
Neuropsychobiology.
2006;
53
133-136
-
24
Kraus T, Reulbach U, Bayerlein K, Mugele B, Hillemacher T, Sperling W. et al .
Leptin is associated with craving in females with alcoholism.
Addict Biol.
2004;
9
213-219
-
25
Kiefer F, Jahn H, Jaschinski M, Holzbach R, Wolf K, Naber D. et al .
Leptin: a modulator of alcohol craving?.
Biol Psychiatry.
2001;
49
782-787
-
26
Nicolas J M, Fernandez-Sola J, Fatjo F, Casamitjana R, Bataller R, Sacanella E. et al .
Increased circulating leptin levels in chronic alcoholism.
Alcohol Clin Exp Res.
2001;
25
83-88
-
27
Wurst F M, Bechtel G, Forster S, Wolfersdorf M, Huber P, Scholer A. et al .
Leptin levels of alcohol abstainers and detoxification patients are not different.
Alcohol Alcohol.
2003;
38
364-368
-
28
Inui A.
Feeding and body-weight regulation by hypothalamic neuropeptides - mediation of the actions of leptin.
Trends Neurosci.
1999;
22
62-67
-
29
Sillaber I, Rammes G, Zimmermann S, Mahal B, Zieglgänsberger W, Wurst W. et al .
Enhanced and delayed stress-induced alcohol drinking in mice lacking functional CRH1-receptors.
Science.
2002;
296
931-933
-
30
Adinoff B, Junghanns K, Kiefer F, Krishnan-Sarin S.
Suppression of the HPA axis stress-response: implications for relapse.
Alcohol Clin Exp Res.
2005;
29
1351-1355
-
31
Cloninger C R, Sigvardsson S, Gilligan S B, Knorring A L von, Reich T, Bohman M.
Genetic heterogeneity and the classification of alcoholism.
Adv Alcohol Subst Abuse.
1988;
7
3-16
-
32
Lesch O M, Walter H.
Subtypes of alcoholism and their role in therapy.
Alcohol Alcohol Suppl.
1996;
1
63-67
-
33
Hillemacher T, Bayerlein K, Wilhelm J, Bonsch D, Poleo D, Sperling W. et al .
Recurrent detoxifications are associated with craving in patients classified as type 1 according to Lesch's typology.
Alcohol Alcohol.
2006;
41
66-69
-
34
Kiefer F, Helwig H, Tarnaske T, Otte C, Jahn H, Wiedemann K.
Pharmacological relapse prevention of alcoholism: clinical predictors of outcome.
Eur Addict Res.
2005;
11
83-91
-
35
Lhuintre J P, Moore N, Tran G, Steru L, Langrenon S, Daoust M. et al .
Acamprosate appears to decrease alcohol intake in weaned alcoholics.
Alcohol Alcohol.
1990;
25
613-622
-
36
Mann K, Lehert P, Morgan M Y.
The Efficacy of Acamprosate in the Maintenance of Abstinence in Alcohol-Dependent Individuals: Results of a Meta-Analysis.
Alcohol Clin Exp Res.
2004;
28
51-63
-
37
Volpicelli J R, Alterman A I, Hayashida M, O'Brien C P.
Naltrexone in the treatment of alcohol dependence.
Arch Gen Psychiatry.
1992;
49
876-880
-
38
Srisurapanont M, Jarusuraisin N.
Opioid antagonists for alcohol dependence.
Cochrane Database Syst Rev.
2005;
25: CD001867
-
39
Anton R F, O'Malley S S, Ciraulo D A, Cisler R A, Couper D, Donovan D M. et al .
Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.
Jama.
2006;
295
2003-2017
-
40 Fachin-Scheit D J, Frozino Ribeiro A, Pigatto G, Oliveira Goeldner F, Boerngen de Lacerda R. Development of a mouse model of ethanol addiction: naltrexone efficacy in reducing consumption but not craving. J Neural Transm 2006
-
41
Kranzler H R, Wesson D R, Billot L.
Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial.
Alcohol Clin Exp Res.
2004;
28
1051-1059
-
42
Garbutt J C, Kranzler H R, O'Malley S S, Gastfriend D R, Pettinati H M, Silverman B L. et al .
Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial.
Jama.
2005;
293
1617-1625
-
43
Wewers M E, Dhatt R, Tejwani G A.
Naltrexone administration affects ad libitum smoking behavior.
Psychopharmacology (Berl).
1998;
140
185-190
-
44
Hillemacher T, Bayerlein K, Wilhelm J, Frieling H, Thürauf N, Ziegenbein M. et al .
Nicotine dependence is associated with compulsive alcohol craving.
Addiction.
2006;
101
892-897
-
45
De Souza A, De Souza A.
An open randomized study comparing disulfiram and acamprosate in the treatment of alcohol dependence.
Alcohol Alcohol.
2005;
40
545-548
-
46
Johnson B A, Ait-Daoud N, Bowden C L, DiClemente C C, Roache J D, Lawson K. et al .
Oral topiramate for treatment of alcohol dependence: a randomised controlled trial.
Lancet.
2003;
361
1677-1685
-
47
Rubio G, Ponce G, Jimenez-Arriero M A, Palomo T, Manzanares J, Ferre F.
Effects of topiramate in the treatment of alcohol dependence.
Pharmacopsychiatry..
2004;
37
37-40
-
48
Kornhuber J, Bormann J, Retz W, Hubers M, Riederer P.
Memantine displaces [3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex.
Eur J Pharmacol.
1989;
166
589-590
-
49
Spanagel R, Kornhuber J.
Glutamatrezeptorantagonisten und Alkoholabhängigkeit.
Nervenarzt.
1999;
70
479-481
-
50
Hölter S M, Danysz W, Spanagel R.
Evidence for alcohol anti-craving properties of memantine.
Eur J Pharmacol.
1996;
314
R1-2
-
51
Hölter S M, Danysz W, Spanagel R.
Novel uncompetitive N-methyl-D-aspartate (NMDA)-receptor antagonist MRZ 2/579 suppresses ethanol intake in long-term ethanol-experienced rats and generalizes to ethanol cue in drug discrimination procedure.
J Pharmacol Exp Ther.
2000;
292
545-552
-
52
Bachteler D, Economidou D, Danysz W, Ciccocioppo R, Spanagel R.
The effects of acamprosate and neramexane on cue-induced reinstatement of ethanol-seeking behavior in rat.
Neuropsychopharmacology.
2005;
30
1104-1110
-
53
Wiesbeck G A, Weijers H G, Althaus M, Mann K, Boening J.
Neramexane, a new NMDA-receptor antagonist in relapse prevention - results of a placebo controlled multicentre “proof-of-concept” study.
Eur Arch Psychiatry Clin Neurosci.
2004;
254 (Suppl. 1)
43
-
54
Backstrom P, Bachteler D, Koch S, Hyytia P, Spanagel R.
mGluR5 antagonist MPEP reduces ethanol-seeking and relapse behavior.
Neuropsychopharmacology.
2004;
29
921-928
-
55
Schroeder J P, Overstreet D H, Hodge C W.
The mGluR5 antagonist MPEP decreases operant ethanol self-administration during maintenance and after repeated alcohol deprivations in alcohol-preferring (P) rats.
Psychopharmacology (Berl).
2005;
179
262-270
-
56
Mason B J, Kocsis J H, Ritvo E C, Cutler R B.
A double-blind, placebo-controlled trial of desipramine for primary alcohol dependence stratified on the presence or absence of major depression.
Jama.
1996;
275
761-767
-
57
Garbutt J C, West S L, Carey T S, Lohr K N, Crews F T.
Pharmacological treatment of alcohol dependence: a review of the evidence.
Jama.
1999;
281
1318-1325
-
58
Bakker M H, McKernan R M, Wong E H, Foster A C.
[3H]MK-801 binding to N-methyl-D-aspartate receptors solubilized from rat brain: effects of glycine site ligands, polyamines, ifenprodil, and desipramine.
J Neurochem.
1991;
57
39-45
-
59
Addolorato G, Caputo F, Capristo E, Domenicali M, Bernardi M, Janiri L. et al .
Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study.
Alcohol Alcohol.
2002;
37
504-508
-
60
Johnson B A, Roache J D, Ait-Daoud N, Zanca N A, Velazquez M.
Ondansetron reduces the craving of biologically predisposed alcoholics.
Psychopharmacology (Berl).
2002;
160
408-413
-
61
Johnson B A, Roache J D, Javors M A, DiClemente C C, Cloninger C R, Prihoda T J. et al .
Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: A randomized controlled trial.
Jama.
2000;
284
963-971
-
62
Mhatre M, Pruthi R, Hensley K, Holloway F.
5-HT3 antagonist ICS 205 - 930 enhances naltrexone's effects on ethanol intake.
Eur J Pharmacol.
2004;
491
149-156
-
63
Rodd-Henricks Z A, McKinzie D L, Edmundson V E, Dagon C L, Murphy J M, McBride W J. et al .
Effects of 5-HT(3) receptor antagonists on daily alcohol intake under acquisition, maintenance, and relapse conditions in alcohol-preferring (P) rats.
Alcohol.
2000;
21
73-85
-
64
Le Foll B, Goldberg S R.
Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence.
J Pharmacol Exp Ther.
2005;
312
875-883
-
65
Serra S, Brunetti G, Pani M, Vacca G, Carai M A, Gessa G L. et al .
Blockade by the cannabinoid CB(1) receptor antagonist, SR 141 716, of alcohol deprivation effect in alcohol-preferring rats.
Eur J Pharmacol.
2002;
443
95-97
-
66
Gessa G L, Serra S, Vacca G, Carai M A, Colombo G.
Suppressing effect of the cannabinoid CB1 receptor antagonist, SR147778, on alcohol intake and motivational properties of alcohol in alcohol-preferring sP rats.
Alcohol Alcohol.
2005;
40
46-53
-
67
Gallate J E, Mallet P E, McGregor I S.
Combined low dose treatment with opioid and cannabinoid receptor antagonists synergistically reduces the motivation to consume alcohol in rats.
Psychopharmacology (Berl).
2004;
173
210-216
-
68
Spanagel R, Siegmund S, Cowen M, Schroff K C, Schumann G, Fiserova M. et al .
The neuronal nitric oxide synthase gene is critically involved in neurobehavioral effects of alcohol.
J Neurosci.
2002;
22
8676-8683
-
69
Nestler E J.
Molecular basis of long-term plasticity underlying addiction.
Nat Rev Neurosci..
2001;
2
119-128
-
70
Wiesbeck G A, Weijers H G, Wodarz N, Lesch O M, Glaser T, Boening J.
Gender-related differences in pharmacological relapse prevention with flupenthixol decanoate in detoxified alcoholics.
Arch Womens Ment Health.
2003;
6
259-262
-
71
Wiesbeck G A, Weijers H G, Lesch O M, Glaser T, Toennes P J, Boening J.
Flupenthixol decanoate and relapse prevention in alcoholics: results from a placebo-controlled study.
Alcohol Alcohol..
2001;
36
329-334
-
72
Mason B J.
Acamprosate and naltrexone treatment for alcohol dependence: an evidence-based risk-benefits assessment.
Eur Neuropsychopharmacol.
2003;
13
469-475
-
73
Kiefer F, Jahn H, Tarnaske T, Helwig H, Briken P, Holzbach R. et al .
Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study.
Arch Gen Psychiatry.
2003;
60
92-99
-
74
Kiefer F, Jahn H, Otte C, Demiralay C, Wolf K, Wiedemann K.
Increasing leptin precedes craving and relapse during pharmacological abstinence maintenance treatment of alcoholism.
J Psychiatr Res.
2005;
39
545-551
-
75
Kiefer F, Jahn H, Otte C, Naber D, Wiedemann K.
Hypothalamic-pituitary-adrenocortical axis activity: a target of pharmacological anticraving treatment?.
Biol Psychiatry.
2006;
60
74-76
-
76
King A C, Schluger J, Gunduz M, Borg L, Perret G, Ho A. et al .
Hypothalamic-pituitary-adrenocortical (HPA) axis response and biotransformation of oral naltrexone: preliminary examination of relationship to family history of alcoholism.
Neuropsychopharmacology.
2002;
26
778-788
-
77
Geer E B, Landman R E, Wardlaw S L, Conwell I M, Freda P U.
Stimulation of the hypothalamic-pituitary-adrenal axis with the opioid antagonist nalmefene.
Pituitary.
2005;
8
115-122
-
78
Bleich S, Lenz B, Ziegenbein M, Beutler S, Frieling H, Kornhuber J. et al .
Epigenetic DNA hypermethylation of the HERP gene promoter induces down-regulation of its mRNA expression in patients with alcohol dependence.
Alcohol Clin Exp Res.
2006;
30
587-591
Dr. med. Thomas Hillemacher
Psychiatrische und Psychotherapeutische Klinik Universitätsklinikum Erlangen
Schwabachanlage 6
91054 Erlangen
eMail: thomas.hillemacher@psych.imed.uni-erlangen.de
